Table 1

 Clinical and biochemical characterisation of patients with non-alcoholic fatty liver disease

SteatosisNASHSteatosis and cirrhosis
Statistically significant versus steatosis plus cirrhosis: *p<0.05; **p<0.01; ***p<0.0001. Statistically significant versus NASH: †p<0.05; ††p<0.0001.
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
No of patients (M/F)79 (54/25)74 (39/35)14 (8/6)
Age (y)51.5 (13.7)**53.6 (13.3)**60.3 (9.9)
Body mass index (kg/m2)32.4 (5.9)*†34.5 (4.7)36.7 (4.4)
Diabetes (%)12 (15)28 (38)9 (64)
AST (U/l)33.8 (15.1)**††47.8 (23.6)50.3 (28.0)
ALT (U/L)56.3 (34.2)†73.8 (50.6)53.5 (51.9)
AST/ALT ratio0.70 (0.29)***0.73 (0.24)***1.28 (0.64)
γ-glutamyl transpeptidase (U/l)85.6 (54.7)**73.3 (49.0)***170.9 (239.3)
Alkaline phosphatase (U/l)86.0 (29.6)**86.6 (33.0)**107 (41.4)
IgG10.91 (2.27)**10.99 (3.29)**15.51 (4.32)
Bilirubin (μmol/l)11.9 (6.3)*10.7 (6.6)*16.0 (9.6)
Ferritin (μg/l)153.2 (112.3)175.9 (106.2)175.0 (193.8)
Cholesterol (mmol/l)6.0 (1.5)***†5.6 (1.1)†4.4 (1.1)
Triglycerides (mmol/l)2.8 (1.8)3.0 (2.0)2.1 (0.9)
Albumin (g/l)45.5 (2.8)***44.7 (3.5)***39.7 (5.6)